title: Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
abstract: BACKGROUND
  When co-administered with interferon and ribavirin, the prescription drug telaprevir significantly improves treatment response in patients with chronic hepatitis C virus (HCV) infection. Its use, however, also increases the likelihood of adverse effects that may lead to discontinuation of treatment. Cutaneous adverse effects are particularly common.
  
  
  OBJECTIVE
  To determine the frequency and clinical characteristics of drug eruptions induced by telaprevir in patients receiving HCV treatment and to analyze the clinical course of lesions and response to treatment.
  
  
  METHODS
  We performed a prospective observational study of all patients who started a treatment regimen that included telaprevir between May 2012 and July 2013. We recorded the demographic characteristics of the patients who developed telaprevir-induced eruptions, and analyzed the clinical characteristics of the lesions and their clinical course following the application of guideline-based treatment recommendations.
  
  
  RESULTS
  Twenty (46%) of the 43 patients who received triple therapy with interferon, ribavirin, and telaprevir during the study period developed drug reactions attributable to telaprevir. The reaction was classified as mild or moderate (grades 1 or 2) in 90% of cases and consisted of an exanthem with erythematous-edematous scaling plaques and papules. The rash worsened, mainly by spreading, in about one-third of cases. The skin lesions led to discontinuation of treatment in 2 patients (4.6%). Sustained viral response was achieved in 34 patients (79%).
  
  
  CONCLUSIONS
  Telaprevir-induced eruptions are common and often progress, but they rarely require patients to discontinue treatment.
authors.affiliation: Servicio de Dermatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España. Electronic address: toromigueli@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Toro Montecinos
authors.affiliation: Servicio de Dermatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: J M
authors.initials: JM
authors.lastname: Carrascosa Carrillo
authors.affiliation: Servicio de Dermatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: M
authors.initials: M
authors.lastname: Vilavella Rius
authors.affiliation: Servicio de Dermatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: I
authors.initials: I
authors.lastname: Bielsa Marsol
authors.affiliation: Servicio de Dermatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: Plana Pla
authors.affiliation: Unidad de Hepatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: R
authors.initials: R
authors.lastname: Morillas Cunill
authors.affiliation: Unidad de Hepatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: R
authors.initials: R
authors.lastname: Planas Vilà
authors.affiliation: Unidad de Hepatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: H
authors.initials: H
authors.lastname: Masnou Ridaura
authors.affiliation: Unidad de Hepatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: D
authors.initials: D
authors.lastname: López Escartin
authors.affiliation: Servicio de Dermatología, Hospital Universitari GermansTrias i Pujol, Badalona, Barcelona, España.
authors.forename: C
authors.initials: C
authors.lastname: Ferrándiz Foraster
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D003875:Drug Eruptions / Q000453:epidemiology / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D015842:Serine Proteinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D009842:Oligopeptides; D015842:Serine Proteinase Inhibitors; D012254:Ribavirin; C486464:telaprevir; D007372:Interferons
keywords: Hepatitis C virus; Telaprevir; Toxicoderma; Toxicodermia; Triple terapia; Triple therapy; Virus hepatitis C